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Summary 
A primate toxicity study was performed to test the hypothesis that BUdR does not increase the likelihood of 
unilateral or bilateral central nervous system damage secondary to radiation therapy. 
BUdR, a halogenated pyrimidine analog is incorporated into DNA of dividing cells and sensitizes them to 
radiation. It is best given unilaterally, intra-arterially by continuous infusion because of its regional advantage 
(Rd) estimated to be between 11 and 16. 
Six rhesus monkeys were implanted with a Model 400 Infusaid pump perfusing the right internal carotid 
artery. Three of the six monkeys received intra-arterial (IA) BUdR infusion plus whole brain external beam 
radiation (6000 R over 6 weeks) and three received radiation alone. 
The two BUdR treated animals completing radiation developed symmetric bilateral high signal aberrations 
on MRI in the frontal, parietal, and occipital centrum semiovale and corona radiata at nine months. At autopsy, 
confluent microinfarcts were found to correspond topographically to the MRI abnormalities. In the radiation 
alone group, two animals had normal MRI and autopsy while the third animal had bilateral MRI high signal 
aberrations develop sequentially with corresponding microinfarcts at autopsy. These changes were greater in 
severity than those seen in the BUdR treated animals. We support previous evidence that there is differential 
intraspecies sensitivity to radiation. We find that BUdR produces no unilateral potentiation of radiation toxici- 
ty. 
Introduction 
Radiation therapy has been shown to be the most ef- 
fective post-surgical single modality treatment for 
malignant astrocytomas, and therapeutic responses 
are dose-dependent [1, 2]. BUdR is a halogenated 
pyrimidine analog that is incorporated into DNA of 
dividing cells in a competitive manner with thymi- 
dine and sensitizes them to radiation therapy [3, 4]. 
It is given unilaterally, intra-arterially by continuous 
infusion because of its R d estimated to be between 
11 and 16 [5]. Therefore the hemisphere ipsilateral to 
the infusion will receive 11-16 times greater BUdR 
concentration than the opposite hemisphere. We 
performed a primate toxicity study to test the 
hypothesis that BUdR does not increase the likeli- 
hood of unilateral or bilateral damage secondary to 
radiation therapy. 
The brain appears to be an ideal site for BUdR 
radio-sensitization, since neurons, glia and endothe- 
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lial cells have a very low mitotic rate, will not take 
up BUdR and, hence, will not be sensitized. Malig- 
nant astrocytomas will incorporate BUdR and be 
radiosensitized. A therapeutic advantage should be 
obtained between tumor and normal brain. Prior to 
beginning a human study of IA BUdR radiosensiti- 
zation in patients with malignant astrocytomas we 
implanted 6 rhesus monkeys with a Model 400 Infu- 
said pump perfusing the right internal carotid artery 
to investigate normal brain toxicity. Three monkeys 
received IA BUdR infusion. All monkeys received 
whole brain external beam radiation. 
Methods 
Six normal rhesus monkeys had a Model 400 Infu- 
said pump implanted in a subcutaneous pocket on 
the right side of the abdomen with the drug outlet 
cathether tunneled subcutaneously and advanced 
retrograde down the right external carotid artery and 
secured so that the orifice of the cathether was at the 
carotid artery bifurcation [6]. All distal branches of 
the external carotid artery were ligated so that a 
purely internal carotid artery infusion was achieved. 
Animals received a 5-day postoperative course of 
antibiotics. At the time of implantation each pump 
was filled with heparinized saline and refilled at bi- 
monthly intervals until optimal wound healing. Af- 
ter one month, 3 monkeys (#1-3) had the pump 
filled with BUdR 10 mg/kg/day (in a carbonate- 
bicarbonate buffer, pH 9.7) containing a 1000 un i t s /  
ml of heparin. The control group (#4-6) received 
the same carbonate-bicarbonate buffer solution 
containing a 1000 units/ml of heparin. The day fol- 
lowing pump fill, all animals began cobalt 60 exter- 
nal beam radiation, which was administered four 
days per week using opposed lateral whole brain 
treatment portals with 250 cGy (rad) midplane dose 
being given daily under general anesthesia with 
Ketamine and Rompun. Total dose was 6000 cGy 
(rad) over 40 elapsed days. Shielding was utilized to 
protect the orbit and pharynx regions. Following 
completion of the radiation all pumps were ex- 
planted. 
MRI was obtained before radiation (baseline) and 
at 3 and 9 months following completion of RT. The 
9 month MRI was immediately prior to sacrifice 
and pathological examination. All MRIs were ac- 
quired with a super conducting 0.35 Tesla Diasonics 
MT/S unit imaging hydrogen protons via spin-echo 
technique. Both spin-lattice relaxation time (TI) 
and spin-spin relaxation time (T2) weighted 5 mm 
axial sections were performed to image the entire 
cranial contents, resulting in an effective resolution 
of 1.8 mm. These used a 128x256 matrix and the 
standard head coil. No paramagnetic contrast was 
employed. Images were interpreted in a single blind 
fashion, qualitatively rating presence or absence of 
signal aberrations and their topographic distribu- 
tion. As the T 2 imager provided the mostsignal 
aberrations they were quantified by assigning a scale 
from least (1 +) to most severe (3 +) signal aberra- 
tions. 
The animals were sacrificed by administration of 
pentobarbital sodium IV until there was cardio- 
respiratory arrest. Complete necropsies were done 
with brain, spinal cord, and somatic tissues removed 
and immersion-fixed in 10% neutral buffered for- 
malin. After 3 weeks fixation, the brain was sliced 
in the coronal plane into 0.5 cm slabs. Identical 
blocks were collectd from each hemisphere including 
prefrontral, frontal, parietal, temporal and occipital 
lobes. Additional bilateral blocks were collected 
from thalamus, hypothalamus, hippocampus, mid- 
brain, pons, cerebellum, medulla and spinal cord. 
These specimens were embedded in paraffin, sec- 
tioned at six#m and stained with hematoxylin-eosin- 
luxol fast blue using standard methods. The slides 
were examined in a single blind fashion. In an effort 
to quantitate histologic lesions all the sections were 
examined with a dissecting microscope at 100x 
magnification. At this level of magnification all le- 
sions equal to or larger than 0.1 mm were tabulated 
for each hemisphere. After all animals had been 
sacrificed and examined, comparison of MRI and 
autopsy results took place by both comparison of 
tabular data and direct comparison of MRI images 
with histologic sections. 
Animal care was provided by the staff of the Unit 
for Laboratory Animal Medicine under the supervi- 
sion of veterinarians by the guidelines provided for 
in 'The Guide for the Care and Use of Laboratory 
Animals', DHEW Publ. No. (NIH) 78-23 Revised 
1978. This included regular periodic surveillance of 
animal facilities, review of programs for humane use 
of animals, and the appropriate use of surgical 
anesthesia, analgesics and tranquilizers. 
Results 
Animal #1 died an anesthetic death after 16 radia- 
tion treatments (Table 1). Animals #2 and 3 (IA 
BUdR + radiation) had normal MRI at baseline and 
3 months, but had bilateral diffuse mild periepen- 
dymal and cortical-medullary junction high signal 
abnormalities develop o n  T 2 weighted sequencies at 
9 months. At autopsy histologic changes were limit- 
ed to the frontal, parietal and occipital centrum 
semiovale and corona radiata. Discrete oval regions 
of pallor on low magnification had a variety of 
histologic changes. The majority of lesions were fo- 
cal necrosis with astrogliosis, mineralization, loss of 
myelin and axons and lipid hemosiderin-laden mac- 
rophages (Fig. la). Rare acute lesions had hemor- 
rhagic necroses with swollen eosinophilic axons and 
edema. Other pale areas had diffuse hypertrophic 
astrocytes (Fig. lb). Some of these microinfarcts 
were associated with vascular changes with massive 
hyalin thickening of the vessel wall (Fig. lc) and 
either endothelial loss or hypertrophy. A few small 
arteries were found with occluded lumens or recanal- 
ized thrombi. Perivascular gliosis was rare and occa- 
sional small perivascular cuffs of mononuclear leu- 
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cocytes were present at the margin of larger lesions. 
Histologic changes were symmetrical on animal #2. 
Animal #3 had more lesions in the non-BUdR- 
perfused hemisphere. 
Animals #4 and 6 (radiation alone) had normal 
MRI at baseline, 3 and 9 months, as well as a normal 
autopsy. Animal #5 (radiation alone) had symmet- 
ric high signal abnormalities o n  T 2 weighted se- 
quences develop between baseline and 3 months 
with these signal aberrations increasing in severity at 
9 months (Fig. 2). Autopsy showed bilateral sym- 
metrical microinfarcts which were greater in number 
than in our BUdR + radiation animals (Fig. 3). 
Correspondence of autopsy and MRI data was good 
with the most marked histologic lesions exactly 
matching the topography of the most marked MRI 
signal aberrations. In no animal was an MRI signal 
aberration identified that did not correspond to a 
confluence of the above described histologic lesions. 
In no animal was a confluence of these lesions found 
on autopsy without a corresponding MRI signal 
aberration. 
Discussion 
Monkeys were chosen as the experimental animal be- 
cause they are similar to man and have an internal 
carotid artery dominant supratentorial brain perfu- 
sion. The radiation dosage schedule was similar to the 
one to be used in our patients with malignant astrocy- 
Table 1. IA BUdR Radiosensitization + radiation therapy (RT) a 
Treatment Animal MRI Signal 
3 months 
Aberrations Histopathology 
9 months (number of micro- 
infarcts 0.1 mm) 
(R) (L) 
BUdR b + RT 1 Anesthetic death 
BUdR b + RT 2 Normal 1+ Mild L,R Frontoparietal 2 
BUdR b + RT 3 Normal 2+ Moderate L,R 3 
RT 4 Normal Normal 0 
RT 5 1 + Mild Symmetric 3 + Severe Symmetric 40 






a Radiation therapy - 6000 cG @ 250 cGy/day 4 days/week × 6 weeks. 
b BUdR-(R) internal carotid system (10 mg/kg/day  x 6 weeks) via implanted Infusaid(R) pump. 
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Fig. 1. Monkey #3. a. Right occipital white matter. A typical 
mineralized microinfarct with adjacent hyalinized small vessels 
(V) and hemosiderin-laden macrophages (M). Horizontal bar 
0.5 mm H-E-luxol fast blue. b. Frontal white matter hyper- 
trophic astrocytes (arrow). Horizontal bar 0.25 mm H-E-luxol 
fast blue. c. Adjacent to 2a hyalin thickening of small vessel 
with attenuated endothelium lined lumen. Horizontal bar 
0.25 mm H-E-luxol fast blue. 
tomas. BUdR was given continuously throughout 
radiation therapy to stimulate planned clinical stud- 
ies in patients with malignant gliomas. Greater expo- 
sure to BUdR would allow maximum incorporation 
into the DNA of  dividing tumor  cells. BUdR dose 
was selected to achieve plasma levels comparable to 
that in our planned clinical study. 
The histology of the cerebral white matter  lesions 
in our primates are similar to those described by 
Caveness in animals treated with doses of  radiation 
conventionally given in whole brain human radia- 
tion (7). In our animals, identically treated monkeys 
showed considerably variation in brain injury. Of  
three animals receiving radiation alone, two (#4, 6) 
had normal  MRI and autopsies while a third (#5) 
demonstrated sequential development of  the most 
severe MRI (T2) high signal abnormalities. We add 
to existing evidence that a differential intraspecies 
sensitivity to radiation exists. 
The MRI  signal aberrations in animal #5 as well 
as similar but less severe abnormalities in #2 and 3 
showed topographic and grade correspondence with 
white matter  microinfarcts at pos tmortem examina- 
tion. Animals #2 and 3 developed bilateral MRI sig- 
nal aberrations at 9 months while animal #5 devel- 
oped sequential changes at 3 and 9 months. These 
lesions were symmetrical in animal #2 and more 
numerous in the non-BUdR perfused hemisphere of  
animal #3. In one animal we were able to image with 
MRI  the sequential changes of  radiation toxicity. 
The biologic basis for the MRI  signal aberrations is 
reported to be secondary to the expected prolonga- 
tion of  T 2 from regional increase in water content as 
seen in edema and gliomas [8]. 
Intra-arterial BUdR produced no additional tox- 
icity ipsilateral to the arterial infusion in the hemi- 
sphere receiving 11-16 times higher concentration 
of  BUdR. However, of  two BUdR animals both had 
bilateral MRI and postmortem changes compared to 
one of  three animals in the control groups. The 
changes in the control animal were most severe. 
Whether the more frequent bilateral toxicity in the 
BUdR treated animals was secondary to IA BUdR, 
where we would expect it to be greater in the ipsilater- 
al hemisphere and where in one animal #3, it was 
greater in the contralateral hemisphere or to dif- 
ferential intraspecies sensisitivity to radiation is un- 
certain. 
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Fig. 2. MRI, monkey #5, nine months. Severe diffuse, symmetric predominantly white matter signal aberrations. (Figure 2b). These are 
most marked in the centrum semiovale (arrows). 
Fig. 3. Monkey #5. Left parietal centrum semiovale. Three 
necrotic microinfarcts, the left most containing axonal minerali- 
zation. Horizontal bar 1.0 mm H-E-luxol fast blue. 
We believe this is a safe model for the future study 
of regionally applied halopyrimidines. Hoshino et  
al. used percutaneous BUdR carotid infusion in 
Japan with a high frequency of cerebral vascular 
complications [9, 10]. Our pump system is implant- 
ed surgically retrograde down the external carotid ar- 
tery. The catheter does not protrude into the internal 
carotid artery, and heparin is placed in the pump to 
prevent thromboembolic complications. The intra- 
venous infusion of BUdR has been accompanied by 
systemic toxicity including diffuse skin rash and 
hematologic toxicity [11, 12]. In recent studies by 
Hoshino et al. with a BUdR monoclonal antibody 
they have found an S phase labelling in glioblastoma 
multiforme varying between 1.3 and 27°7o [13]. This 
indicates that a prolonged constant infusion may be 
necessary for BUdR to be incorporated into and sen- 
sitize all cells. We hope R d of BUdR will enable us 
to use a lower radiation dose with increase thera- 
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peu t i c  e f fec t  a n d  less sys temic  toxici ty.  
We have  b e g u n  a P h a s e  I c l in ica l  t r ia l  ( N C I  P r o -  
t o c o l  T-83-101) in pa t i en t s  w i t h  G r a d e  I I I - I V  m a l i g -  
n a n t  a s t r o c y t o m a s .  Th i s  e m p l o y s  I n f u s a i d  p u m p  
p l a c e m e n t  fo r  e ight  weeks  I A  ca ro t i d  B U d R  i n f u s i o n  
[6]. Foca l  ex te rna l  b e a m  r a d i a t i o n  t h e r a p y  is del iv-  
e red  t h e  las t  six weeks  o f  B U d R  in fus ion .  
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